18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
NCT ID: NCT03741231
Last Updated: 2019-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2018-03-01
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or Melanoma
NCT03584334
Modeling of the Response to Hypofractionated Stereotactic Pulmonary Irradiation
NCT03175861
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma
NCT05645484
Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers
NCT01421953
Imaging NSCLC Treatment Response to Immunotherapy
NCT02753569
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Multicentric retrospective study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients treated in Brest, Morlaix, Landerneau hospital
* patients performed FDG PET
* no opposition to study
Exclusion Criteria
* refusal to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Brest
Brest, , France
CH de LANDERNEAU
Landerneau, , France
Centre Hospitalier de Morlaix
Morlaix, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMMUNOPET ( 29BRC17.0253).
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.